[{"id":"4baf504a-3428-46d7-aa11-1c6d5b48f340","acronym":"ACTION-1","url":"https://clinicaltrials.gov/study/NCT05477576","created_at":"2022-07-28T14:55:31.876Z","updated_at":"2025-02-25T17:37:59.568Z","phase":"Phase 3","brief_title":"Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","source_id_and_acronym":"NCT05477576 - ACTION-1","lead_sponsor":"RayzeBio, Inc.","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • lanreotide prolonged-release subcutaneous • octreotide acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 288","initiation":"Initiation: 03/24/2022","start_date":" 03/24/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-01-29"},{"id":"0a7abb08-ccb1-4e69-80bd-9e92b2a533e2","acronym":"NETTER-2","url":"https://clinicaltrials.gov/study/NCT03972488","created_at":"2021-02-11T16:53:55.907Z","updated_at":"2024-07-02T16:35:03.576Z","phase":"Phase 3","brief_title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","source_id_and_acronym":"NCT03972488 - NETTER-2","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 226","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 07/20/2023","primary_completion_date":" 07/20/2023","study_txt":" Completion: 10/29/2027","study_completion_date":" 10/29/2027","last_update_posted":"2024-05-15"},{"id":"5cfe778d-fe5e-47ad-9d92-bcdc82f98727","acronym":"SORENTO","url":"https://clinicaltrials.gov/study/NCT05050942","created_at":"2021-09-21T11:53:31.080Z","updated_at":"2024-07-02T16:35:22.027Z","phase":"Phase 3","brief_title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","source_id_and_acronym":"NCT05050942 - SORENTO","lead_sponsor":"Camurus AB","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous • Oclaiz (octreotide subcutaneous depot) • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 332","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-26"},{"id":"1ae2a3a3-6728-4257-87af-f63fd6f956aa","acronym":"NETTER-1","url":"https://clinicaltrials.gov/study/NCT01578239","created_at":"2021-01-18T06:42:58.061Z","updated_at":"2024-07-02T16:36:14.196Z","phase":"Phase 3","brief_title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","source_id_and_acronym":"NCT01578239 - NETTER-1","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • octreotide acetate"],"overall_status":"Completed","enrollment":" Enrollment 231","initiation":"Initiation: 09/06/2012","start_date":" 09/06/2012","primary_txt":" Primary completion: 07/31/2015","primary_completion_date":" 07/31/2015","study_txt":" Completion: 01/18/2021","study_completion_date":" 01/18/2021","last_update_posted":"2022-04-04"},{"id":"cb54d783-3aff-40e1-81ee-683128ab09b0","acronym":"MetNET1","url":"https://clinicaltrials.gov/study/NCT02294006","created_at":"2021-06-10T09:54:24.459Z","updated_at":"2024-07-02T16:36:24.698Z","phase":"Phase 2","brief_title":"Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs","source_id_and_acronym":"NCT02294006 - MetNET1","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • metformin • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2021-09-09"},{"id":"a17ecf97-42a3-44d1-a1f4-cff3903f10f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00002864","created_at":"2021-01-17T22:48:48.119Z","updated_at":"2024-07-02T16:36:46.983Z","phase":"Phase 3","brief_title":"Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer","source_id_and_acronym":"NCT00002864","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" PGR","pipe":"","alterations":" ","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Soltamox (tamoxifen citrate) • octreotide acetate"],"overall_status":"Completed","enrollment":" Enrollment 667","initiation":"Initiation: 09/24/1996","start_date":" 09/24/1996","primary_txt":" Primary completion: 12/07/2007","primary_completion_date":" 12/07/2007","study_txt":" Completion: 04/23/2010","study_completion_date":" 04/23/2010","last_update_posted":"2020-04-01"},{"id":"dcf070b8-c1c9-42c7-86fb-590929bf423e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02299089","created_at":"2021-01-18T10:50:48.870Z","updated_at":"2025-02-25T15:42:05.057Z","phase":"Phase 2","brief_title":"Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)","source_id_and_acronym":"NCT02299089","lead_sponsor":"Camurus AB","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Oclaiz (octreotide subcutaneous depot) • octreotide acetate • octreotide acetate solution for injection"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2017-12-15"},{"id":"dbad78d8-facd-49a8-8a54-303be42ec140","acronym":"","url":"https://clinicaltrials.gov/study/NCT01371643","created_at":"2021-01-18T05:37:07.136Z","updated_at":"2024-07-02T16:37:29.515Z","phase":"Phase 4","brief_title":"Surgical Debulking of Pituitary Adenomas","source_id_and_acronym":"NCT01371643","lead_sponsor":"NYU Langone Health","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e octreotide acetate"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 04/01/2004","start_date":" 04/01/2004","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 12/01/2011","study_completion_date":" 12/01/2011","last_update_posted":"2016-08-29"}]